StockData

Harmony Biosciences vs Ionis Pharmaceuticals

HRMY and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HRMY and IONS compare

Ionis Pharmaceuticals is the larger company, worth 2.3 times as much as Harmony Biosciences ($4.5B against $1.9B).

Harmony Biosciences grew revenue faster over the last twelve months (24.3% versus −7.4% for Ionis Pharmaceuticals).

Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −64.7% at Ionis Pharmaceuticals.

Harmony Biosciences scores higher on the StockData Score (18 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHRMYIONS
Size and price
Market cap$1.9B$4.5B
Share price$33.01$26.96
Change, 1 year−3.0%−62.3%
Change, 5 years−12.1%−7.2%
Beta (5Y)1.110.60
Employees2931,402
StockData Score
Total score18 (better)4
Valuation score6 (better)1
Growth score22
Performance score4 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/E10.7×–
P/S2.0× (better)5.1×
P/B1.9× (better)10.2×
EV/EBITDA6.1×–
FCF yield–−12.5%
Fair value$53.99$27.86
Margin of safety38.9% (better)3.2%
Growth
Revenue growth (TTM)24.3% (better)−7.4%
Revenue growth, 5Y average40.3% (better)5.3%
Net income growth (TTM)0.20%–
EPS growth (TTM)−0.32%–
Profitability
Gross margin75.4%98.2% (better)
Operating margin24.0% (better)−68.0%
Net margin18.9% (better)−64.7%
FCF margin–−64.2%
Return on equity20.5% (better)−105%
Return on invested capital40.1%–
Financial health
Debt / equity0.15–
Net debt / EBITDA−2.23–
Interest coverage17.1× (better)−31.6×
Current ratio3.487.89 (better)
Altman Z-score5.12 (better)0.23
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.0%108%
Held by insiders12.1%0.81%
Insider net buying, 12 months−$5.8M (better)−$114M
Superinvestors holding–1
Short interest, % of float13.0%12.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.